glp-1 agonists and retained gastric contents at endoscopy Hold GLP-1s Before Endoscopy? Clinical Trial Finds Effects of Glucagon-Like Peptide-1 Receptor

Two major ongoing trials are likely to change that, with potentially big implications for clinical practice.

Conclusion GLP-1 RA therapy has a respiratory safety profile that is neither uniformly benign nor hazardous, stratified by mechanism, agent subclass, and clinical context

Currently, there are ten classes of orally available pharmacological agents to treat T2DM: 1) sulfonylureas, 2) meglitinides, 3) metformin (a biguanide), 4) thiazolidinediones (TZDs), 5) alpha glucosidase inhibitors, 6) dipeptidyl peptidase IV (DPP-4) inhibitors, 7) bile acid sequestrants, 8) dopamine agonists, 9) sodium-glucose transport protein 2 (SGLT2) inhibitors and 10) oral glucagon like peptide 1 (GLP-1) receptor agonists

A small human proof-of-concept trial reported that semaglutide reduced vastus lateralis cross-sectional area but did not reduce knee-extension strength or grip strength over 12 weeks

Metabolic Benefits: Along with weight loss, it has shown promising results in treating Type 2 diabetes, with some studies showing hemoglobin A1c reductions

Learn ways to save on Contrave costs.